Jignesh S Kotecha
☆    

India,
2019-05-12 18:53

Posting: # 20280
Views: 446
 

 Abridged application for modified release forms [Regulatives / Guidelines]

We are developing a prolonged release tablet for Europe market. This product has got single strength. The therapeutic doses is achieved with this single strength by increasing the number of tablets per day in three divided doses. These doses should be attained slowly, by step-wise increase by one tablet every two weeks.

We are required to conduct a single dose fasting, single dose fed and multiple dose study in fed condition. Since this product has single strength and dose is increased to therapeutic level step-wise, can we conduct the multiple dose study at given strength considering it as a sensitive strength?


Edit: Please follow the Forum’s Policy[Helmut]
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,567 posts in 4,150 threads, 1,340 registered users;
online 5 (0 registered, 5 guests [including 5 identified bots]).
Forum time (Europe/Vienna): 00:44 CEST

Mediocrity knows nothing higher than itself,
but talent instantly recognizes genius.    Arthur Conan Doyle

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5